<DOC>
	<DOCNO>NCT02910882</DOCNO>
	<brief_summary>This single arm phase II trial assess potential activity combination PEGPH20 plus Gemcitabine radiotherapy ten patient localize , unresectable pancreatic adenocarcinoma .</brief_summary>
	<brief_title>PEGPH20 Plus Gemcitabine With Radiotherapy Patients With Localized , Unresectable Pancreatic Cancer</brief_title>
	<detailed_description>This pilot trial evaluate safety potential efficacy PEGylated Recombinant Human Hyaluronidase ( PEGPH20 ) plus concurrent Gemcitabine radiotherapy . Recognizing PEGPH20 previously deliver radiotherapy unlikely contribute increase toxicity , trial abbreviate sequential dose escalation schema first three patient . PEGPH20 give twice per week first 28 day weekly another 2 week radiotherapy . Gemcitabine deliver weekly first day radiotherapy continued weekly , per publish literature . Patients remain study three month . The duration active treatment PEGPH20 Gemcitabine plus radiotherapy continue 5-6 week . Efficacy outcome occur 6-8 week completion radiotherapy .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Subjects must satisfy follow inclusion criterion enrol study : 1 . Signed , write Institutional Review Board/Ethics Committeeapproved Informed Consent Form ; 2 . For men woman reproductive potential , agreement use effective contraceptive method time screen throughout time study . Effective contraceptive method consist prior sterilization , intrauterine device , oral injectable contraceptive , and/or barrier method . Abstinence alone consider adequate contraceptive measure purpose study ; 3 . Patients previously untreated localize , unresectable histologically confirm pancreatic adenocarcinoma ( unresectable define locally advanced disease patient refuse surgery ) ; 4 . Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L ; 5 . Platelets ≥ 100 x 109/L ; 6 . Hgb ≥ 9 g/dL ; 7 . Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) ≤ 2.5 x [ Upper Limit Normal ( ULN ) ] ; 8 . Bilirubin ≤ 1.5 x ULN ; 9 . GFR ≥ 30 mL/min ; 10 . Patient clinically significant abnormality urinalysis result ; 11 . Patient acceptable coagulation status indicate Prothrombin Time ( PT ) Partial Thromboplastin Time ( PTT ) within 15 % normal limit ; 12 . Eastern Cooperative Oncology Group ( ECOG ) ≤ 2 Subjects ineligible enrollment meet follow exclusion criterion : 1 . Clinical evidence deep vein thrombosis ( DVT ) , pulmonary embolism ( PE ) know thromboembolic ( TE ) event present screening period ; 2 . Any prior history cerebrovascular accident , transient ischemic attack , preexist carotid artery disease . 3 . Known allergy hyaluronidase ; 4 . Current use megestrol acetate ( use within 10 day Day 1 ) ; 5 . Contraindication heparin include prior heparin induce thrombocytopenia ( HIT ) , recent CNS bleed ; intracranial spinal lesion high risk bleeding ; severe platelet dysfunction ; recent major operation high risk bleeding ; underlie hemorrhagic coagulopathy ; high risk fall ; potential need spinal anesthesia/lumbar puncture ; active bleeding ; 6 . Women currently pregnant breastfeed ; 7 . Intolerance dexamethasone ; 8 . Inability comply study followup procedure judge Investigator ; 9 . Patient active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy ; 10 . Patient known infection HIV , hepatitis B , hepatitis C ; 11 . Patient history allergy hypersensitivity agent suppose receive ( excipients agent ) ; 12 . Patient serious medical risk factor involve major organ system investigator considers unsafe patient receive experimental research drug , include New York Heart Association Functional Class ≥ 3 , myocardial infarction within past 12 month screen , preexist atrial fibrillation , symptomatic COPD . 13 . Patient unwilling unable comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pancreas Cancer</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Chemoradiation</keyword>
	<keyword>PEGPH20</keyword>
</DOC>